Delving into the Latest Updates on PharmaCore Biotech Co., Ltd. with Synapse

Overview

Tags

Neoplasms

Nervous System Diseases

Cardiovascular Diseases

Monoclonal antibody

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Nervous System Diseases	1
Neoplasms	1
Endocrinology and Metabolic Disease	1

Top 5 Drug Type	Count

Small molecule drug	1
Monoclonal antibody	1

Top 5 Target	Count

LAG3(Lymphocyte activation gene 3 protein)	1
Free radicals	1

Primary objective: To evaluate the safety of multiple administrations of LT3001 for injection in the treatment of patients with acute ischemic stroke (AIS). Secondary objective: To evaluate the effectiveness of multiple administrations of LT3001 for injection in the treatment of patients with acute ischemic stroke (AIS).

Start Date06 Apr 2023

Sponsor / Collaborator

Lumosa Therapeutics Co., Ltd.

[+2]

CTR20202357

/ CompletedPhase 1

一项在健康中国成人受试者中评价多剂量LT3001制剂的安全性、耐受性和药代动力学的双盲、随机、安慰剂对照的I期研究

[Translation] A double-blind, randomized, placebo-controlled, phase I study to evaluate the safety, tolerability, and pharmacokinetics of multiple doses of LT3001 in healthy Chinese adult subjects

主要目的：（1）评价注射用LT3001多次给药的安全性与耐受性。（2）评价注射用LT3001多次给药的药代动力学（PK）特征。次要目的：（1）评价注射用LT3001多次给药对血压的影响。（2）评价注射用LT3001多次给药对凝血功能的影响。

[Translation]

Primary objectives: (1) To evaluate the safety and tolerability of multiple administrations of LT3001 for injection. (2) To evaluate the pharmacokinetic (PK) characteristics of multiple administrations of LT3001 for injection. Secondary objectives: (1) To evaluate the effect of multiple administrations of LT3001 for injection on blood pressure. (2) To evaluate the effect of multiple administrations of LT3001 for injection on coagulation function.

Start Date29 Dec 2020

Sponsor / Collaborator

Lumosa Therapeutics Co., Ltd.

[+2]

CTR20191854

/ CompletedPhase 1

Anti-LAG-3单克隆抗体注射液（LBL-007）在晚期实体瘤和晚期淋巴瘤患者中安全性、耐受性、药代动力学及有效性的Ⅰa期临床试验

[Translation] A Phase Ia clinical trial of the safety, tolerability, pharmacokinetics and efficacy of anti-LAG-3 monoclonal antibody injection (LBL-007) in patients with advanced solid tumors and advanced lymphomas

评价LBL-007在晚期实体瘤、晚期淋巴瘤患者中单次给药及多次给药的安全性和耐受性，探索其最大耐受剂量和剂量限制性毒性。评价药代动力学（PK）特征、免疫原性、受体占位率与疗效关系及血液生物标志物的特征。

[Translation]

To evaluate the safety and tolerability of single and multiple administrations of LBL-007 in patients with advanced solid tumors and advanced lymphomas, and to explore its maximum tolerated dose and dose-limiting toxicity. To evaluate the pharmacokinetic (PK) characteristics, immunogenicity, the relationship between receptor occupancy and efficacy, and the characteristics of blood biomarkers.

Start Date31 Dec 2019

Sponsor / Collaborator

PharmaCore Biotech Co., Ltd.

[+1]

100 Clinical Results associated with PharmaCore Biotech Co., Ltd.

Login to view more data

0 Patents (Medical) associated with PharmaCore Biotech Co., Ltd.

Login to view more data

100 Deals associated with PharmaCore Biotech Co., Ltd.

Login to view more data

100 Translational Medicine associated with PharmaCore Biotech Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 16 Sep 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 2

2

Login to view more data